Blood immune cell profiling in people with autoimmune diseases
Studies immune cell types in blood of people with lupus, arthritis and related conditions.
Plain-language title generated from the registry record
Registry title: Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-70 with an autoimmune disease such as lupus, rheumatoid arthritis, Sjogren's syndrome or gout. Blood samples are used to study immune cells.
- Age
- 18-70 years
- Sex
- Men and women
- Disease stage
- Active disease. The diagnosis must meet the listed classification standard for each disease and the disease activity index.
- Earlier treatment
- Glucocorticoid up to 1mg/kg/d prednisone (or equivalent) before joining is allowed, and DMARDs such as methotrexate or hydroxychloroquine are allowed. Recent IVIg, cyclophosphamide, biological agents, rituximab or high-dose glucocorticoid is not allowed.
Main reasons for not taking part
- Recent IVIg, cyclophosphamide, other biological agents, rituximab or high-dose glucocorticoid (more than 1 mg/kg/d)
- Serious heart, kidney or liver problems
- Serious infection, including hepatitis, pneumonia or tuberculosis
- HIV or hepatitis C infection
- Any cancer now or in the past 5 years, or any vaccination within 3 months
Read by machine on 9 November 2026.
Where in China
- Peking University People's HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07188285
- Record updated
- 26 August 2026
- Original description
Based on mass spectrometry flow method, this study analyzed the typing of new T, B, NK and DC cell subsets in peripheral blood of common autoimmune diseases and their correlation with disease activity, aiming at establishing an early screening and diagnosis model of autoimmune diseases.Read full original descriptionShow less
Mass Spectrometry-based Immune Profiling in Peripheral Blood of Autoimmune Diseases
Based on mass spectrometry flow method, this study analyzed the typing of new T, B, NK and DC cell subsets in peripheral blood of common autoimmune diseases and their correlation with disease activity, aiming at establishing an early screening and diagnosis model of autoimmune diseases.
Inclusion: Male or female, and aged 18-70 at the time of screening interview (inclusive); The diagnosis of each disease meets the following standards - Systemic lupus erythematosus: 1997 ACR lupus classification standard; Behcet's disease: 2014 ICBD Behcet's disease classification standard; ANCA-associated vasculitis: 1990 American College of Rheumatology Classification Standard; Rheumatoid arthritis: 1987 ARA classification standard; Ankylosing spondylitis: new york standard revised in 1984; Sjogren's syndrome: 2016 ACR/EULAR Sjogren's syndrome classification standard; Inflammatory myopathy: Bohan recommended criteria in 1977; Systemic sclerosis: SSc standard formulated by American Rheumatology Association in 1980; Psoriatic arthritis: CASPAR standard in 2006; Gouty arthritis: 1997 ACR gout classification standard; Disease activity status, each disease should meet the disease activity index; Glucocorticoid (≤1mg/kg/d prednisone or other hormones with equivalent dose) was used before joining the group, and DMARDs (such as methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, leflunomide, cyclosporine, etc.) were allowed; When participating in the trial, the patient must be informed in writing and hope that the patient can abide by the requirements of the research follow-up plan and other protocols.
Exclusion: Suffering from serious infection (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, EB virus, tuberculosis infection), or being hospitalized due to infection, or using intravenous antibiotics to treat infection 2 months before the first dose of treatment; Chest imaging showed abnormalities of malignant tumor or current active infection (including tuberculosis) within 3 months before enrollment; Other serious, progressive or uncontrollable hematological, gastrointestinal, endocrine, lung, heart, nerve or brain diseases (including demyelinating diseases, such as multiple sclerosis); Any known malignant tumor or history of malignant tumor in the past 5 years. 9. Received any vaccination within 3 months before joining the group; Use IVIg or cyclophosphamide within 1.2 months, use other biological agents (infliximab, adalimumab, etanercept, anakinra, etc.) within 3 months, and use rituximab within 6 months; 2.1 months after receiving high-dose glucocorticoid (> 1 mg/kg/d). 3. Serious complications: including heart failure (≥ NYHA III), renal insufficiency (creatinine clearance rate ≤30 ml/min) and hepatic insufficiency (serum ALT or AST is greater than three times the normal upper limit, or total bilirubin is greater than the normal upper limit); Infected with HIV(HIV antibody positive serology) or hepatitis C (Hep C antibody positive serology). If the serum is positive, it is recommended to consult a doctor with expertise in treating HIV or hepatitis C virus infection.